Table 2 Cost-effectiveness analysis results (main analysis – Societal perspective)
HE + PA | |||||||||
Outcome measure | Sample size | ∆C (95%CI) | ∆E (95%CI) | ICER | Distribution CE-plane (%) | ||||
Intervention | Control | € | Points | €/point | NE | SE | SW | NW | |
Gestational weight gain | 107 | 104 | 380 (−811 to 1510) | −2.3 (−3.7 to −0.9) | −165 | 73.6 | 26.4 | 0.0 | 0.0 |
Fasting glucose | 107 | 104 | 380 (−811 to 1510) | 0.0 (−0.2 to 0.1) | −9198 | 52.9 | 20.2 | 6.3 | 20.7 |
HOMA-IR | 107 | 104 | 380 (−811 to 1510) | 0.0 (−0.1 to 0.2) | 8971 | 47.4 | 16.2 | 10.1 | 26.2 |
QALYs | 107 | 104 | −1627 (−4000 to 556) | 0.02 (0.00 to 0.04) | −91,254 | 7.8 | 88.8 | 3.0 | 0.4 |
HE | |||||||||
Outcome measure | Sample size | ∆C (95%CI) | ∆E (95%CI) | ICER | Distribution CE-plane (%) | ||||
Intervention | Control | € | Points | €/point | NE | SE | SW | NW | |
Gestational weight gain | 114 | 104 | 648 (−482 to 1759) | −0.6 (−2.4 to 1.2) | −1058 | 66.1 | 9.8 | 3.5 | 20.5 |
Fasting glucose | 114 | 104 | 648 (−482 to 1759) | 0.1 (0.0 to 0.3) | 5247 | 2.7 | 0.7 | 12.6 | 83.9 |
HOMA-IR | 114 | 104 | 648 (−482 to 1759) | 0.2 (0.0 to 0.3) | 4302 | 80.5 | 12.2 | 1.2 | 6.2 |
QALYs | 114 | 104 | 653 (−1997 to 3343) | 0.00 (−0.02 to 0.02) | −241,959 | 24.9 | 12.9 | 18.7 | 43.6 |
PA | |||||||||
Outcome measure | Sample size | ∆C (95%CI) | ∆E (95%CI) | ICER | Distribution CE-plane (%) | ||||
Intervention | Control | € | Points | €/point | NE | SE | SW | NW | |
Gestational weight gain | 110 | 104 | 710 (−486 to 1875) | 0.2 (−1.4 to 1.7) | 4810 | 34.4 | 7.6 | 7.1 | 50.9 |
Fasting glucose | 110 | 104 | 710 (−486 to 1875) | 0.0 (−0.1 to 0.1) | −74,480 | 48.8 | 8.9 | 5.8 | 36.6 |
HOMA-IR | 110 | 104 | 710 (−486 to 1875) | 0.1 (−0.1 to 0.3) | 11,292 | 61.7 | 10.6 | 4.1 | 22.7 |
QALYs | 110 | 104 | −1155 (−3473 to 1142) | 0.00 (−0.03 to 0.01) | 146,179 | 2.9 | 16.3 | 65.9 | 14.8 |